Candel Therapeutics Publishes Phase 3 Data Showing Aglatimagene Extends Prostate Cancer Survival

Candel Therapeutics (CADL) published Phase 3 trial results for its gene therapy candidate aglatimagene on June 2, 2026, demonstrating a statistically significant improvement in disease-free survival for men with high-risk localized prostate cancer. The findings, which appeared in a peer-reviewed medical journal, showed that combining aglatimagene with standard radiation therapy led to superior survival outcomes versus radiation alone. The company did not immediately disclose detailed efficacy figures, including the magnitude of the survival benefit. Candel plans to present the full dataset at an upcoming oncology conference and initiate discussions with U.S. regulators. The positive readout positions aglatimagene as a potential new standard-of-care option in a market with limited innovation beyond radiation and hormonal therapies.